Runx1 promotes B-cell survival and lymphoma development

被引:40
作者
Blyth, Karen [1 ]
Slater, Nicholas [1 ]
Hanlon, Linda [1 ]
Bell, Margaret [1 ]
Mackay, Nancy [1 ]
Stewart, Monica [1 ]
Neil, James C. [1 ]
Cameron, Ewan R. [1 ]
机构
[1] Univ Glasgow, Fac Vet Med, Inst Comparat Med, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland
关键词
Runx1; AML1; Mouse; Lymphoma; Myc; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; TRANSCRIPTION FACTOR; INSERTIONAL MUTAGENESIS; AML1/PEBP2-ALPHA-B GENE; ADULT HEMATOPOIESIS; POINT MUTATIONS; CD4; REPRESSION; EXPRESSION; AML1;
D O I
10.1016/j.bcmd.2009.01.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Runx1 is essential for the homeostatic control of normal hematopoiesis and is required for lymphoid development. Translocations or point mutations that result in RUNX1 loss or disrupted function predispose to leukemia but data derived from model systems suggests that Runx genes can also be pro-oncogenic. Here we investigate the effects of enforced Runx1 expression in lymphoid lineages both in vivo and in vitro and show that transgene expression enhanced cell survival in the thymus and bone marrow but strongly inhibited the expansion of hematopoietic and B cell progenitors in vitro. Despite this, modestly enhanced levels of Runx1 accelerated Myc-induced lymphomagenesis in both the B cell and T cell lineages. Together these data provide formal proof that wild type Runx1 can promote oncogenesis in lymphoid tissues and that, in addition to loss of function, gain of function may have an aetiological role in leukemia. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 19
页数:8
相关论文
共 74 条
[1]   Reduction of runx1 transcription factor activity up-regulates Fas and Bim expression and enhances the apoptotic sensitivity of double positive thymocytes [J].
Abe, N ;
Kohu, K ;
Ohmori, H ;
Hayashi, K ;
Watanabe, T ;
Hozumi, K ;
Sato, T ;
Habu, S ;
Satake, M .
JOURNAL OF IMMUNOLOGY, 2005, 175 (07) :4475-4482
[2]   THE C-MYC ONCOGENE DRIVEN BY IMMUNOGLOBULIN ENHANCERS INDUCES LYMPHOID MALIGNANCY IN TRANSGENIC MICE [J].
ADAMS, JM ;
HARRIS, AW ;
PINKERT, CA ;
CORCORAN, LM ;
ALEXANDER, WS ;
CORY, S ;
PALMITER, RD ;
BRINSTER, RL .
NATURE, 1985, 318 (6046) :533-538
[3]   Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector [J].
Adams, JM ;
Harris, AW ;
Strasser, A ;
Ogilvy, S ;
Cory, S .
ONCOGENE, 1999, 18 (38) :5268-5277
[4]  
[Anonymous], 1994, Manipulating the mouse embryo: a laboratory manual
[5]   The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications [J].
Asou, N .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 45 (02) :129-150
[6]   Acute lymphoblastic leukemia and chromosome 21 [J].
Berger, R .
CANCER GENETICS AND CYTOGENETICS, 1997, 94 (01) :8-12
[7]   AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression [J].
Bernardin-Fried, F ;
Kummalue, T ;
Leijen, S ;
Collector, MI ;
Ravid, K ;
Friedman, AD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (15) :15678-15687
[8]   Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo [J].
Blyth, K ;
Vaillant, F ;
Hanlon, L ;
Mackay, N ;
Bell, M ;
Jenkins, A ;
Neil, JC ;
Cameron, ER .
CANCER RESEARCH, 2006, 66 (04) :2195-2201
[9]   The RUNX genes: Gain or loss of function in cancer [J].
Blyth, K ;
Cameron, ER ;
Neil, JC .
NATURE REVIEWS CANCER, 2005, 5 (05) :376-387
[10]   Apparent bypass of negative selection in CD8(+) tumours in CD2-myc transgenic mice [J].
Cameron, ER ;
Campbell, M ;
Blyth, K ;
Argyle, SA ;
Keanie, L ;
Neil, JC ;
Onions, DE .
BRITISH JOURNAL OF CANCER, 1996, 73 (01) :13-17